BDAZ would you know off hand then how similar the SoC for BETOnMACE would be to the SoC for EXAMINE? Given the low usage of SGLT2 inhibitors and GLP1-R agonists in BoM one might think the SoC for both trials is at least similar? If so perhaps one could expect similar placebo event rates?